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Cellular senescence is implicated in several pathological responses in the adult, with important
repercussions in tumor suppression, wound healing, and aging. Two studies by Mun˜oz-Espı´n
et al. and Storer et al. now reveal that senescence contributes to embryonic development, suggest-
ing a primordial role in normal physiology.Seminal studies by Hayflick and Moor-
head demonstrated that normal cells can
only divide a finite number of times before
they reach a state of replicative cellular
senescence. Although we now believe
that senescence plays wider roles in
various stress responses in the adult, in
this issue, Mun˜oz-Espı´n et al. (2013) and
Storer et al. (2013) report the surprising
result that senescence occurs under
physiological conditions during mamma-
lian embryonic development.
Cells undergoing replicative senes-
cence downregulate cell-cycle genes
and certain extracellular matrix compo-
nents while upregulating genes encoding
cell-cycle inhibitors, matrix degrading
enzymes, particular cytokines, and immu-
nosurveillance factors. Cellular stresses
such as telomere uncapping or activation
of oncogenes can trigger stable cell-cycle
arrest programs with similar features,
though whether different ‘‘types’’ of
senescence exist has been debated
(Shay and Roninson, 2004). The most
widely used senescence marker is senes-
cence-associated b-galactosidase activ-
ity (SAbG), which likely reflects the
increased autophagy occurring in senes-
cent cells (Young et al., 2009). Other
canonical senescence markers include
p53, p21, p16, and reduced RB phos-
phorylation, which collectively mediate
the ancillary phenotypic manifestations
of senescence-associated cell-cycle
arrest. Affected cells often accumulate
heterochromatic foci that may stabilize
the senescent state, and they display
altered secretory profiles that modulate
immune function and/or reinforce cell-
cycle arrest (Kuilman et al., 2010). A
conceptual problem is that none of these
markers are unique to senescent cells,and no single marker is sufficient to
‘‘diagnose’’ the senescent state. As a
consequence, senescence has been
defined by a collection of markers that
are not decisive.
Senescence has been largely viewed
as a stress response program. Still, hints
that senescence can play some physio-
logic role came from studies implicating
senescence in limiting certain wound-
healing responses (Jun and Lau, 2010;
Krizhanovsky et al., 2008). Although
SAbG activity has been reported in the
regressing mesonephros of birds (Nacher
et al., 2006), its relevance, if any, in
mammalian embryos remained unknown.
The new reports imply that senescence
occurs throughout mouse development.
Mun˜oz-Espı´n et al. focused on the inner
ear and the regressing mesonepheric
tubules, whereas Storer et al. concen-
trated on the apical ectodermal ridge
(AER) during limb formation. Both studies
imply that ‘‘developmental senescence’’
shares some, but not all, regulatory path-
ways observed in the adult (Figure 1).
Both senescent states share SAbG
activity and senescence-associated
heterochromatin markers (HP1g and
H3K9me3), and both show reduced Ki67
staining (a proliferation marker) owing to
a G1 arrest. However, developmental
senescence does not appear to involve
the activation of p16 or p19ARF and is
not triggered by p53 or DNA damage.
Instead, developmental senescence is
mediated by p21 in a p53-independent
manner but controlled instead by the
TGFb/SMAD- and PI3K/FOXO-signaling
pathways. Although senescent cells in
the embryo and adult each secrete
factors that engage the immune system
to eliminate cells and remodel tissues,Cell 155, Nthe secreted cytokines and growth fac-
tors are not all the same (Figure 1).
At issue is whether these phenomena
indeed represent different types of
senescence or, instead, reflect funda-
mentally different processes. Consistent
with the above observations, p53 or
Ink4a/Arf knockout mice do not present
alterations in patterns of SAbG activity
during development and do not manifest
abnormalities in tissues in which senes-
cence was observed. However, p21 null
embryos revealed fewer SAbG-positive
cells compared to controls and exhibited
detectable developmental abnormalities
in the associated tissues. Yet many of
these embryonic defects are corrected
in neonates. There are at least two
plausible reasons why the phenotype
of p21 null mice might not provide a
readout of the program’s potential
importance. First, it is possible that p21
deletion is not sufficient to override
senescence or may only delay its induc-
tion. Second, the embryo may compen-
sate for p21 loss by engaging alternative
tissue-remodeling programs.
The possibility that compensatory
mechanisms may mask key roles of
certain programs in development is not
without precedent. Compelling evidence
exists for the importance of apoptosis in
embryonic development; yet, disruption
of the intrinsic apoptotic program in the
embryo produces only modest pheno-
types. As one example, apoptosis is
considered a major cell death mechanism
in the developing limbs, but inactivation
of proapoptotic genes in the mouse
only partially prevents the removal of the
interdigital tissues (Fuchs and Steller,
2011). Apparently a compensatory pro-
gram exists to instruct morphogenesisovember 21, 2013 ª2013 Elsevier Inc. 977
Figure 1. Main Features of Senescence in the Adult and in the
Embryo
Whereas the first is induced by stress, such as telomere uncapping, oncogenic
signals, or DNA damage, the second is induced by still undetermined
developmental cues. Both programs share a set of features such as senes-
cence-associated b-galactosidase activity (SAbG), senescence-associated
heterochromatic foci (SAHF), and some of the members of the senescence-
associated secretory phenotype (SASP) such as TGFb, Wnt, and IGFBP family
ligands. Nevertheless, differences exist. Developmental senescence does not
depend on the activation of DNA damage response, p53-21, or p16 tumor
suppressor pathways and does not present some of the SASP-related factors
such as IL8 (Cxcl1, 2, and 5 homologs in mice) and IL6. Although additional
regulatorsmay exist, senescence in the embryo ismainly mediated by p21 and
regulated by the TGFb/SMAD- and FOXO/PI3K-signaling pathways. Tissue
remodeling is a main consequence of both programs. By recruiting the
immune system, senescence mediates the elimination of unwanted/transient
cells or structures. Developmental senescence may additionally dictate the
balance between cell populations or instruct developmental processes.and tissue remodeling when
apoptosis fails. Conversely,
failure of senescence in p21
null mesonephric tubules is
followed by delayed activa-
tion of apoptosis and by
macrophage-mediated clear-
ance of dying cells. It will
be interesting to determine
whether senescence can
compensate for apoptosis
deficiency during develop-
ment.
So, what are the potential
roles for senescence in em-
bryonic development? That
senescence and macro-
phage infiltration precede
mesonephros involution sug-
gests that one role of senes-
cence is to remodel the em-
bryonic kidney. Senescence
may also have an instructive
function. Indeed, Storer et al.
find that the expression
signature in the AER partially
overlaps with that of onco-
gene-induced senescence,
suggesting that secreted
components from senescent
cells influence pattern for-
mation and proliferation of
the adjacent mesenchyme.
Finally, by halting the pro-
liferation of specific cells
within developing tissues,
senescence may dictate the
balanced outgrowth of and
interplay between distinct
cell populations. An exampleof this phenomenon may occur in the
endolymphatic sac, which is not elimi-
nated during development but instead
undergoes a process of differential
cellular proliferative arrest that changes
the relative abundance of distinct cell
populations.
Perhaps the most important ramifi-
cation of the new work relates to its
implications for the evolutionary origin of
the senescence program. Most research
to date has focused on senescence as
a tumor-suppressive process, and it
has been debated as to how evolution
selects for programs that prevent a disor-
der that typically occurs after reproduc-
tive age (Campisi, 2003). The new work
raises the possibility that senescence in978 Cell 155, November 21, 2013 ª2013 Elsethe adult evolved from a primordial
tissue-remodeling program that takes
place in the embryo. In both settings, cells
arrest in the cell cycle, partially share a
common set of functional markers, have
an active role in modifying the tissue
microenvironment, and are ultimately
recognized and cleared by the immune
system (Figure 1). These features may
have been adapted as part of an emer-
gent adult stress response program that
incorporated additional tumor suppressor
mechanisms, such as those reliant on
p53 and p16, to eliminate damaged cells
and that may, in turn, contribute to
organismal aging.
These studies represent another
landmark in the senescence field butvier Inc.also raise a new range of
pertinent questions. What are
the developmental cues that
trigger senescence in the em-
bryo, and to what extent does
this process reflect the stress-
induced senescence program
studied so far? What are the
salient features that define a
cellular senescent state?
Perhaps, as our understand-
ing of cellular senescence
progresses, the hallmarks
and implications of this pro-
cess will broaden and evolve.
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